Hartmut Strobel

Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Uncoupling

Many cardiovascular diseases are associated with reduced levels of bioactive nitric oxide (NO) and an uncoupling of oxygen reduction from NO synthesis in endothelial NO synthase (eNOS uncoupling). In human endothelial EA.hy 926 cells, two small-molecular-weight compounds with related structures, 4-fluoro-N-indan-2-yl-benzamide (CAS no. 291756-32-6; empirical formula C16H14FNO; AVE9488) and 2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid indan-2-ylamide (CAS no. 450348-85-3; empirical formula C17H13F2NO3; AVE3085), enhanced eNOS promoter activity in a concentration-dependent manner; with the responsible cis-element localized within the proximal 263 base pairs of the promoter region. RNA interference-mediated knockdown of the transcription factor Sp1 significantly reduced the basal activity of eNOS promoter, but it did not prevent the transcription activation by the compounds. Enhanced transcription of eNOS by AVE9488 in primary human umbilical vein endothelial cells was associated with increased levels of eNOS mRNA and protein expression, as well as increased bradykinin-stimulated NO production. In both wild-type C57BL/6J mice and apolipoprotein E-knockout (apoE-KO) mice, treatment with AVE9488 resulted in enhanced vascular eNOS expression. In apoE-KO mice, but not in eNOS-knockout mice, treatment with AVE9488 reduced cuff-induced neointima formation. A 12-week treatment with AVE9488 or AVE3085 reduced atherosclerotic plaque formation in apoE-KO mice, but not in apoE/eNOS-double knockout mice. Aortas from apoE-KO mice showed a significant generation of reactive oxygen species. This was partly prevented by nitric-oxide inhibitor Nω-nitro-l-arginine methyl ester, indicating eNOS uncoupling. Treatment of mice with AVE9488 enhanced vascular content of the essential eNOS cofactor (6R)-5,6,7,8-tetrahydro-l-biopterin and reversed eNOS uncoupling. The combination of an up-regulated eNOS expression and a reversal of eNOS uncoupling is probably responsible for the observed vasoprotective properties of this new type of compounds.

Release of nitric oxide from endothelial cells stimulated by YC‐1, an activator of soluble guanylyl cyclase

In this study we examined the endothelium‐dependent effect of YC‐1–a benzyl indazole derivative which directly activates soluble guanylyl cyclase (sGC)–on vascular relaxation and nitric oxide (NO) and guanosine‐3′,5′‐cyclic monophosphate (cyclic GMP) in endothelial cells. In preconstricted rat aortic rings with intact endothelium, YC‐1 produced a concentration‐dependent relaxation. However, the concentration response curve was shifted rightward to higher concentrations of YC‐1, when (i) the aortas were pre‐treated with L‐NG‐nitroarginine methylester (L‐NAME) or (ii) the endothelium was removed. Incubation of bovine aortic endothelial cells (BAEC) with YC‐1 produced a concentration‐dependent NO synthesis and release as assessed using a porphyrinic microsensor. Pre‐incubating cells with L‐NAME or with 8‐bromo‐cyclic GMP decreased this effect indicating that the YC‐1 stimulation of NO synthesis is due to an activation of nitric oxide synthase, but not to an elevation of cyclic GMP. No direct effect of YC‐1 on recombinant endothelial constitutive NO synthase activity was observed. The YC‐1 stimulated NO release was reduced by 90%, when extracellular free calcium was diminished. In human umbilical vein endothelial cells (HUVEC), YC‐1 stimulated intracellular cyclic GMP production in a concentration‐ and time‐dependent manner. Stimulation of cyclic GMP was greater with a maximum concentration of YC‐1 compared to calcium ionophore A23187. Similar effects were observed in BAEC and rat microvascular coronary endothelial cells (RMCEC). When HUVEC and RMCEC were pre‐treated with L‐NG‐nitroarginine (L‐NOARG), the maximum YC‐1 stimulated cyclic GMP increase was reduced by 50%. These results indicate, that beside being a direct activator of sGC, YC‐1 stimulates a NO‐synthesis and release in endothelial cells which is independent of elevation of cyclic GMP but strictly dependent on extracellular calcium. The underlying mechanism needs to be determined further.

Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors

A new series of IGF-1R inhibitors related to hydantoins were identified from a lead originating from HTS. Their noncompetitive property as well as their slow binding characteristics provided a series of compounds with unique selectivity and excellent cellular activities.

Role of the sGC activator ataciguat sodium (HMR1766) in cardiovascular disease

Background Soluble guanylate cyclase (sGC), the key transducer of nitric oxide (NO) signaling, exists in two redox forms: the NO sensitive ferrous heme iron (Fe(II)) form and a NO insensitive oxidized form containing the ferric heme iron (Fe(III)). Ataciguat sodium (further named ataciguat) predominantly stimulates the oxidized form of sGC. To further define the therapeutic potential of ataciguat in cardiovascular disease, we investigated its effect in various in vivo models of: platelet aggregation, atherosclerosis and peripheral arterial occlusive disease.

Role of activators of ferric sGC in cardiovascular disease

Soluble guanylyl cyclase (sGC), the key transducer of nitric oxide (NO) signalling in vascular smooth muscle cells and platelets, exists in two redox forms: the NO-sensitive ferrous heme-iron (Fe(II)) form and a NO-insensitive oxidized form containing the ferric heme-iron (Fe(III)). HMR1766 (proposed INN ataciguat sodium) reversibly stimulates the oxidized form of sGC (crude and purified) in various species and organs to about 10 to 30 % of the maximal activity achieved with NO donors. Acute treatment with HMR1766 has anti-ischemic (acute coronary stenosis) and anti-thrombotic (coronary thrombosis) effects in dog models at doses that did not influence arterial blood pressure or other hemodynamic parameters.